← All trials
NCT06336317
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 24, 2024
- Primary completion
- Dec 31, 2027
- Completion date
- Dec 31, 2027
- First posted
- Mar 28, 2024
- Last posted
- May 3, 2024
- Enrollment
- 90
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Orebro UniversityLead sponsor
- University of CambridgeCollaborator
- Orebro UniversityOfficial
- The Heart and Lung foundation, SwedenCollaborator
- Orebro UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.